Try our mobile app

Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

Published: 2021-12-17 23:09:00 ET
<<<  go to ARGX company page
  • VYVGART is the first and only FDA-approved neonatal Fc receptor blocker
  • 68% of anti-acetylcholine receptor (AChR) antibody positivegMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis - Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p